- Home
- SRM vs NERV Comparison
SRM vs NERV Comparison
Compare SRM & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRM
- NERV
- Stock Information
- Founded
- SRM 1979
- NERV 2007
- Country
- SRM United States
- NERV United States
- Employees
- SRM N/A
- NERV N/A
- Industry
- SRM
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- SRM
- NERV Health Care
- Exchange
- SRM Nasdaq
- NERV Nasdaq
- Market Cap
- SRM 9.0M
- NERV 12.4M
- IPO Year
- SRM 2023
- NERV 2014
- Fundamental
- Price
- SRM $0.42
- NERV $1.59
- Analyst Decision
- SRM
- NERV Hold
- Analyst Count
- SRM 0
- NERV 1
- Target Price
- SRM N/A
- NERV $5.00
- AVG Volume (30 Days)
- SRM 519.7K
- NERV 7.7K
- Earning Date
- SRM 05-20-2025
- NERV 05-20-2025
- Dividend Yield
- SRM N/A
- NERV N/A
- EPS Growth
- SRM N/A
- NERV N/A
- EPS
- SRM N/A
- NERV 0.19
- Revenue
- SRM $4,311,382.00
- NERV N/A
- Revenue This Year
- SRM N/A
- NERV N/A
- Revenue Next Year
- SRM N/A
- NERV N/A
- P/E Ratio
- SRM N/A
- NERV $8.42
- Revenue Growth
- SRM N/A
- NERV N/A
- 52 Week Low
- SRM $0.26
- NERV $1.15
- 52 Week High
- SRM $1.66
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- SRM 55.93
- NERV 46.58
- Support Level
- SRM $0.39
- NERV $1.65
- Resistance Level
- SRM $0.46
- NERV $1.75
- Average True Range (ATR)
- SRM 0.06
- NERV 0.08
- MACD
- SRM 0.01
- NERV -0.00
- Stochastic Oscillator
- SRM 59.09
- NERV 31.03
About SRM SRM Entertainment Inc.
SRM Entertainment Inc is a trusted toy and souvenir designer and developer, selling into theme parks and entertainment venues. It has developed, manufactured, and supplied the entertainment and amusement park industry with exclusive products that are often only available to consumers inside SRM's customer base venues such as Walt Disney Parks and Resorts, Universal Studios, SeaWorld, Six Flags, Great Wolf Lodge, Dollywood, and Merlin Entertainment. Its product category includes The Smurfs and Zoonicorns, Sammy Sloth, lilita Llama, kyle Koala, and Hanna Hedgehog.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.